

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1.-11. Canceled.

12. (Previously Presented) A method of testing the stability to degradation of a solid pharmaceutical dosage form comprising lamotrigine, which method comprises assaying the said sample for the presence of 3-amino-6-(2,3-dichlorophenyl)-1,2,4-triazine-5-(4H)-one.

13. Canceled.

14. (Previously Presented) A method according to claim 12 for testing the stability to degradation of a solid pharmaceutical dosage form comprising lamotrigine, which includes the steps of:

(i) dissolving a sample of the dosage form in a solvent to produce a sample solution;

(ii) dissolving a sample of 3-amino-6-(2,3-dichlorophenyl)-1,2,4-triazine-5-(4H)-one in a solvent to produce a reference marker standard solution;

(iii) subjecting the sample solution and the standard solution to thin layer chromatography to obtain a TLC chromatogram for each; and

(iv) estimating the intensity of any secondary spot obtained in the chromatogram of the sample solution, which corresponds in Rf value to the reference marker, against the spot due to the reference marker in the chromatogram of the standard solution.

15. (Previously Presented) A method according to claim 12 for testing the stability to degradation of a solid pharmaceutical dosage form comprising lamotrigine, which includes the steps of:

(i) dissolving a sample of the dosage form in a solvent to produce one or more sample solutions;

(ii) dissolving a sample of lamotrigine reference standard in a solvent to produce a standard solution;

(iii) injecting the sample and standard solutions on to an HPLC column, and

(iv) determining the main peak areas of each solution and calculating from these the content of the reference marker

3-amino-6-(2,3-dichlorophenyl)-1,2,4-triazine-5-(4H)-one in the sample solution.